BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma
BioAtla's Mecbotamab Vedotin , an AXL-targeting ADC, Demonstrates a Median Overall Survival of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma at the Annual Conference of the International Papillomavirus Society
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA
SAGA Metals Completes HQ Drill Program for Planned Metallurgical Pilot Study Associated with PEA / PFS - Level Evaluation at Radar Critical Minerals Project
Centurion to Resume Trading and Provides Update on Option to Acquire the Brothers Gold Project, Suriname
